Call it the 150-day wonder. The formation of Allogene Therapeutics, which took off with a $300 million series A financing and a portfolio of assets from Pfizer Inc. related to allogeneic chimeric antigen receptor T cell (CAR T) therapy, began with a conversation at a dinner on Nov. 3, 2017, celebrating the close of another big deal: the acquisition of autologous CAR T therapy player Kite Pharma Inc. by Gilead Sciences Inc.